Login / Register Order My Items
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Oncology Peptide–Drug Conjugation

Cancer drug–focused oncology peptide–drug conjugation for research-stage and preclinical peptide–drug conjugates (PDCs).

Custom oncology PDC synthesis using payload-aware, site-defined strategies (project-dependent).

Request a Quote Contact a Chemist
Talk to a chemist Request a quote
Overview Oncology drugs Related services FAQ Reading Contact

Oncology Peptide–Drug Conjugation Overview

Oncology peptide–drug conjugation involves covalently linking a small‑molecule cancer drug to a peptide carrier through a defined chemical linker, forming a peptide–drug conjugate (PDC). This strategy is widely explored in oncology research to combine the pharmacological activity of anticancer drugs with the targeting, transport, or binding properties of peptides. [1], [2]

In these constructs, the oncology drug payload (e.g., paclitaxel, doxorubicin, kinase inhibitors) is the primary driver of biological activity, while the peptide component may influence tumor association, cellular uptake, or biodistribution. Linker chemistry and attachment site selection are critical for controlling stability and heterogeneity. [3]

Branched peptide synthesis schematic showing a lysine branching core with two to eight peptide arms (MAP-2, MAP-4, MAP-8) and dendrimer for multivalent epitope presentation.

Bio-Synthesis services: Custom oncology peptide–drug conjugation using payload-aware, site-defined strategies to support reproducible research and preclinical development (project-dependent).

Paclitaxel (Taxol) Docetaxel Doxorubicin Irinotecan / SN-38 Etoposide EGFR inhibitors

Oncology Drug Payload Examples (From Your List)

The drug names below are oncology (cancer) drugs from your list, organized by class for clarity. Final feasibility for peptide–drug conjugation is project-dependent and depends on functional handles, stability, and linker strategy.

Drug class Oncology drugs (examples) Notes for peptide–drug conjugation
Anthracyclines & antitumor antibiotics Doxorubicin, Epirubicin, Daunorubicin, Idarubicin, Elsamicin A, Actinomycin D, Bleomycin, Mithramycin, Mitoxantrone, Mitomycin Often have defined conjugation handles; reaction conditions should preserve payload integrity.
Microtubule inhibitors Paclitaxel (Taxol), Docetaxel, Tesetaxel, Vincristine, Vinblastine, Vinorelbine (Navelbine), Demecolcine Hydrophobic payloads may require spacers/solubilizing strategy (project-dependent).
Topoisomerase inhibitors Etoposide (VP-16), Irinotecan, Topotecan Attachment position should avoid disrupting key pharmacophores.
Platinum agents Cisplatin, Carboplatin Conjugation approaches are more constrained; feasibility is highly chemistry-dependent.
Alkylating agents Busulfan, Nitrogen mustards, Uramustine, Chlorambucil, Melphalan, Cyclophosphamide, Ifosfamide, Carmustine, Lomustine, Semustine, Procarbazine, Dacarbazine Reactivity can drive linker/handle selection; plan to protect sensitive motifs.
Antimetabolites Methotrexate, Pemetrexed, Tegafur-uracil, Mercaptopurine, Thioguanine, Cytarabine (Ara-C), Gemcitabine, Capecitabine, Nelarabine, Fludarabine, Cladribine (Leustatin), Hydroxyurea Often used in comparative payload studies; solubility varies by compound.
Targeted small-molecule inhibitors Erlotinib, Lapatinib Preserve inhibitor pharmacophore; site selection is critical.
Biologics (not small molecules) Bevacizumab (Avastin), Rituximab, Tumor necrosis factor (TNF) These are antibodies/cytokines; they fit ADC/bioconjugation workflows more than small-molecule PDC payloads.

Excluded (not cancer drugs in your list): Praziquantel (antiparasitic), Lamivudine (antiviral), Ambroxol (mucolytic), CCP / 3-cyano-2-chloropyridine (chemical intermediate).

Use Cases in Oncology PDC Research

  • Targeted delivery studies using cytotoxic payloads (e.g., paclitaxel/Taxol, doxorubicin) to evaluate uptake and selectivity.
  • Comparative payload screening to benchmark different oncology drug payloads on the same peptide scaffold.
  • Linker stability and release hypothesis testing under tumor-relevant biological conditions (project-dependent).
  • Structure–function optimization of peptide carriers, attachment site, and spacer/linker strategy to reduce heterogeneity.

Bio-Synthesis support: We help plan feasible conjugation routes and fit-for-purpose analytical characterization aligned to these study goals (project-dependent).

Our Quality Commitment

  • ISO-aligned quality systems and controlled laboratory workflows
  • Payload-aware conjugation planning to preserve oncology drug integrity
  • Site-defined conjugation strategies to reduce batch heterogeneity
  • Purification by HPLC or UPLC tailored to peptide–drug conjugates
  • Analytical characterization by LC-MS or fit-for-purpose methods (when feasible)
  • Documentation and reporting aligned with research and preclinical needs

All oncology peptide–drug conjugation services are provided for research and preclinical use. Final specifications and analytical scope are project-dependent.

FAQ

Can Bio-Synthesis perform site-specific oncology PDC synthesis?

Yes. Site-defined attachment strategies such as N-terminus, C-terminus, single-cysteine, or handle-enabled chemistries are commonly used to reduce heterogeneity and improve reproducibility in oncology peptide–drug conjugates.

Are cleavable linkers available for oncology peptide–drug conjugates?

Cleavable linker concepts (e.g., enzyme-, pH-, or redox-responsive) can be evaluated when controlled payload release is desired. Linker selection is guided by the oncology drug, peptide sequence, and intended biological environment.

Which oncology drugs are suitable for peptide–drug conjugation?

Many small-molecule cancer drugs can be evaluated for peptide conjugation, including paclitaxel (Taxol), docetaxel, doxorubicin, epirubicin, irinotecan/SN-38, etoposide, methotrexate, and selected kinase inhibitors. Feasibility depends on functional groups, stability, and linker strategy (project-dependent).

What information is needed to request an oncology PDC quote?

To request a quote, please provide the peptide sequence(s), oncology drug payload (structure or catalog number), preferred attachment site or constraints, target quantity, and intended application. This allows evaluation of feasible conjugation routes and analytical requirements.

More FAQ'sAll FAQ's

Contact & quote request

For the fastest quote on oncology peptide–drug conjugation services, share your peptide sequence(s), payload structure or catalog #, preferred attachment site/constraints, linker preference (or ask for a recommendation), and quantity/purity targets.

Fastest path
Request a Quote Speak to a Chemist
Fast quote checklist
  • Peptide sequence(s) + termini state + reactive handles (Cys/Lys/azide/alkyne)
  • Payload name + structure (or catalog #) + any solubility constraints (e.g., paclitaxel/Taxol, doxorubicin, irinotecan/SN-38, kinase inhibitors)
  • Attachment site preference (or “recommend best site”)
  • Linker preference (stable vs cleavable; if cleavable, what trigger)
  • Quantity (mg), purity target, intended use, and timeline constraints

Speak to a Scientist

Full Name *
Email *
Company / Institution *
Phone *
Notes *Please avoid confidential details; we can arrange an NDA if needed.

By submitting, you agree to be contacted regarding your request.

972-420-8505 (USA) 800-227-0627 (INTL.) info@biosyn.com Contact Us

Recommended Reading on Oncology Peptide–Drug Conjugates

  • Cooper, B. M.; Iegre, J.; O’Connor, C. J.; et al. Peptide–drug conjugates: recent advances and future directions. Chemical Society Reviews, 2021. https://pubs.rsc.org/…/d0cs00362g
  • Wang, M.; Zhang, Y.; Feng, J.; et al. Peptide–drug conjugates in cancer therapy: design strategies and applications. European Journal of Medicinal Chemistry, 2024. https://www.sciencedirect.com/…
  • Hoyt, E. A.; Cal, P. M. S. D.; Oliveira, B. L.; Bernardes, G. J. L. Contemporary approaches to site-selective protein and peptide modification. Nature Reviews Chemistry, 2019. https://www.nature.com/…
  • Böhme, D.; Beck-Sickinger, A. G. Drug delivery and release systems for targeted cancer therapy. Journal of Peptide Science, 2015. https://onlinelibrary.wiley.com/…

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 40+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links